Can you describe Exyte as a company and more specific the Biopharma Life Sciences work done by the firm?
Exyte offers the full suite of engineering, design, procurement, construction, construction management, qualification and validation services to highly complex projects on behalf of the world’s leading biopharma and life sciences multinational and regional clients. The company is trusted by clients to provide these services in various delivery models to include feasibility, conceptual, basic, and detailed design, as well as Engineer Procure and Construct (EPC) and Construction Management at risk with or without qualification services. Exyte takes on overall responsibility for quality assurance and delivering the project within the set timeframe and budget while assuming and managing risk for the project.
The biopharma and life sciences sector is a key component in Exyte’s target ‘Pathway to Ten’, the goal to reach annual sales of 10 billion Euro. The company’s biopharma and life sciences business places a sharp focus on client prerequisites in delivering facilities and manufacturing plants for top-tier companies while operating in five global regions; the USA, Northern Europe and Israel, Continental Europe, Southeast and Northeast Asia. Exyte’s clients are working tirelessly to bring crucial pharmaceuticals, biotechnology, consumer care and medical devices to market and secure international supply lines.
Exyte biopharma and life science business benefits from long-term relationships resulting in orders from global clients with whom we have worked in cooperation for many years. Exyte is committed to strong client relationships and global integrated project delivery to drive further growth of biopharma business in all five of our operating regions. We leverage technology to deliver more with our automated design, intelligent construction, digitalization, and innovative modular solutions for our clients. Our commitment to sustainability influences all that we do in our operations for our clients and our communities.
What makes Exyte so unique and how do we differentiate from the competition?
The rapid changes in the pharma and biopharma industry have brought challenges and opportunities. Exyte has achieved significant growth in the sector because of our innovative and flexible approach to project execution by accepting manageable risk associated with accelerated integrated design-build and EPC delivery while incorporating modular and off-site solutions while maintaining a focus on predictability of delivery, which is key for our clients. Exyte is a safe pair of hands.
How does Exyte translate its global biopharma and life science knowledge into the services that we will provide in the US?
We are recognized by both global and regional based clients as a fully integrated engineering, design and construction partner. We have built successful business relationships with these clients in all of operating regions. We intend to bring this expertise and align it with our growing and diversified USA region-based teams to deliver the same type of project success. We have made a substantial investment in attracting top level biopharma and life sciences talent into our USA team far in advance of new work coming into the door. We believe we need to demonstrate to our clients that we are ready to execute on Day 1.
We fully intend to leverage our innovative products and services into the USA market. For example, our ExyCell® modular solution is a high-quality modular system tailored to meet client needs to reduce time-to-market, ensure cost certainty, and enhance safety and quality to biomanufacturing production facilities. The system with pre-configured and prefabricated modules has proven highly successful on several projects in delivering the fast-track construction of biopharma production facilities developed by Exyte. Despite its standardization, it can be adapted to local requirements and conditions. To accommodate room configurations ranging from a single room to four rooms, various ventilation options can be installed. We have completed our ExyCell® demonstration facility in our Raleigh, North Carolina office.
What is the primary reason for the establishments in PA and NC?
North Carolina and Pennsylvania are the location of choice for those in the biopharma and life sciences industry. Both states are home to a thriving life science community, highly skilled workforce, top-ranking academic and research climate, which accelerates success in the life sciences. Top talent, infrastructure and a business-friendly climate are among the reasons why Exyte chose these areas to expand its business. In addition to its vision, as an industry leader, Exyte looks to continue sustainable growth in the US, based on a strong performance with a reputation for industry knowledge and project delivery management.
How does Exyte foresee employees being a part of the growth and reaching into new markets in PA and NC?
As mentioned before, we have made a substantial talent investment in both our Raleigh and Philadelphia offices. We are ready now to deliver all scopes of the project lifecycle for both our global and regional clients. Underpinning our existing talent base, is our absolute cultural commitment to Diversity and Inclusion with a One-Team approach to identify and promote ambitious teams who bring expertise and energy to each client and every project. Respectful engagement within their multicultural environment is part of the Exyte ethos and philosophy and offers our USA teams the chance to interact with colleagues around the globe to discuss and debate best practices and industry mandated technical expertise by sharing knowledge globally.
Where are the PA and NC offices located and how can the clients reach us?
Our office locations in NC and PA are readily available on our website as is the entire Exyte global office footprint. You can find this information via (Insert direct office website link on Exyte.net)
What does success look like for Exyte in PA and NC?
We anticipate the USA biopharma and life sciences market to be Exyte’s largest and most successful region within the next three years. The USA is the world’s leading market and dramatic changes in pharmaceutical applications are being driven by technical innovations such as mRNA, Cell and Gene Therapies and other market changing innovations.
We expect significant investment in PA and NC not only in the new innovations discussed, but traditional projects to include active pharmaceutical ingredients, aseptic production, monoclonal antibodies, oral solid dosage, sterile fill finish, GMP warehouses, etc. Success will be fully achieved when Exyte is considered one of the top “go to” firms in the USA market for projects delivering these facilities to meet these client and patient needs.
Where do you see Exyte’s expansion in the US in 5 years?
We expect to grow our professional teams in both Raleigh and Conshohocken significantly in the next five years. We will have a very strong eastern US presence with an intention to head west as our client’s needs evolve.
Are we recruiting at the moment and how can one apply?
We are constantly looking for new talent. Visit https://careers.exyte.net/ to explore the wide variety of exciting positions.
To learn more about employees’ experience at Exyte, #exytecareersareexciting
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!